Navigation Links
MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
Date:3/9/2009

obtain an immediate supply of insulin and the ability to supply our insulin needs for the future, even if we are unable to acquire the facility itself. We are pleased with this opportunity to secure our insulin supply, which brings AFRESA one step closer to commercial readiness."

Additional information about this transaction is available in a Current Report on Form 8-K filed by MannKind with the Securities and Exchange Commission earlier today.

About AFRESA(R)

AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The pharmacokinetic profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung provides unique access to the circulatory system. The pH-sensitive AFRESA particles immediately dissolve upon contact with the lung surface, releasing insulin monomers that rapidly enter the bloodstream. It achieves peak insulin levels within 12-14 minutes of administration, effectively mimicking the release of meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscri
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
2. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
5. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
6. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
7. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
8. MannKind to Present at the UBS Global Life Sciences Conference
9. MannKind Corporation Reports Second Quarter Financial Results
10. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
11. MannKind to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015  Metanome, Inc., an ... the company has changed its name to Diversigen, ... positioning as the single commercial source for the ... capitalize on the diverse opportunities of the microbiome. ... Diversigen accepts – including those that are difficult ...
(Date:4/23/2015)... 2015 Delpor, Inc. (Delpor), a biotechnology ... United States Patent and Trademark Office has issued 2 ... technology. US Pat. No. 8,986,727 was issued on ... delivery device for the sustained release of therapeutic ... the sustained (zero-order) release of large and small molecules ...
(Date:4/22/2015)... April 22, 2015   MPIRICA Health Inc. ... $1.6M in Series A financing from the McQuinn ... helps accelerate consumer and employer awareness of MPIRICA.com, ... at over 4,800 U.S. hospitals. "As ... probably very concerned about choosing the hospital and ...
(Date:4/22/2015)... (PRWEB) April 22, 2015 ... medical devices market witnessed tremendous growth primarily ... and increasing government support with increased nanotechnology ... , Request Customization: , http://www.marketsandmarkets.com/requestCustomization.asp?id=65048077 ... medical devices market is segmented on the ...
Breaking Biology Technology:Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3MPIRICA Health Inc. Secures $1.6M to Promote FICO-Like Quality Scores for Surgeries 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 2Nanotechnology-based Medical Devices Market to Reach Around $8.5 billion by 2019 - Published by MarketsandMarkets 3
... 11 Altogen Biosystems,( http://www.altogen.com ) announced ... Las Vegas, NV, Altogen Custom Services focus ... Interference (RNAi) services, generation of stably-expressing cell,lines, ... the company will draw upon their unique ...
... affordable and accessible to all researchers, HUNTSVILLE, ... that Harvard Medical School and the University of ... Each University,purchased access to whole genome human and ... and distributed by Open Biosystems., (Logo: ...
... China-based R&D and production platform and Datascope,s strong US-based ... direct sales and service network, Provides powerful ... ... SHENZHEN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ...
Cached Biology Technology:Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Open Biosystems' Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 2Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 3Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 4Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 5Mindray to Acquire Datascope's Patient Monitoring Business for US$202 million 6
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... popular designer cannabis products called "Spice" or "K2" have ... researchers is reporting progress toward understanding what makes them ... Analytical Chemistry , describes development of a method ... thousands of young adults and teens who end up ...
... for Parkinson,s Research and Shake It Up Australia Foundation ... Institute of Medical Research to look at the role ... non-coding RNAs are complex molecules, produced from a DNA ... body. Unlike conventional genes, they do not make proteins ...
... of strong design competence and cutting-edge cellulose-based technologies ... aim is for fibre from wood-based biomass to ... and polyester production, which consumes oil. A research ... Finland, Aalto University and Tampere University of Technology ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Finland to lead the way as a designer of cellulose-based products 2Finland to lead the way as a designer of cellulose-based products 3
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
... Kinase. This product is expected ... other mammalian species but has not ... a single precipitin line against partially ... shown to react with all forms ...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... tube handling and reagent dispensing Holds: ... - 96 x 0.3ml U-bottom Omnistrips ... Non-Skirted Plate - Thermo-Fast® 96 Semi-Skirted Plate ... Multiple workstations can be securely stacked Can be stored ...
Biology Products: